NCT03921775

Brief Summary

The study is being conducted to evaluate the efficacy and safety of remimazolam tosilate compared to propofol for general anesthesia during elective surgery.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
330

participants targeted

Target at P50-P75 for phase_3

Timeline
Completed

Started May 2019

Shorter than P25 for phase_3

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 15, 2019

Completed
4 days until next milestone

First Posted

Study publicly available on registry

April 19, 2019

Completed
24 days until next milestone

Study Start

First participant enrolled

May 13, 2019

Completed
8 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 30, 2019

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 30, 2019

Completed
Last Updated

May 15, 2020

Status Verified

May 1, 2020

Enrollment Period

8 months

First QC Date

April 15, 2019

Last Update Submit

May 14, 2020

Conditions

Outcome Measures

Primary Outcomes (1)

  • Percentage(%) of paticipants who experienced successful anesthesia during operation in each group

    Average of 2 hours

Secondary Outcomes (3)

  • Time from start of investigational medicinal product administration to loss of consciousness

    Average of 2 hours

  • Time from stop of investigational medicinal product to MOAA/S Score=5

    Average of 2 hours

  • Time from stop of investigational medicinal product to Aldrete Score>9

    Average of 2 hours

Study Arms (2)

Treatment group A

EXPERIMENTAL

IV pumping of remimazolam tosilate at 6mg/kg/h for anesthesia induction and 1mg/kg/h for anesthesia maintenance

Drug: Remimazolam Tosilate

Treatment B

ACTIVE COMPARATOR

IV pumping of propofol at 120\~150mg/kg/h for anesthesia induction and 3\~12mg/kg/h for anesthesia maintenance

Drug: Propofol

Interventions

For induction and maintenance of general anesthesia

Treatment group A

For induction and maintenance of general anesthesia

Treatment B

Eligibility Criteria

Age18 Years - 60 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may not qualify if:

  • Patients scheduled for emergency surgery
  • Patients with a history of drug abuse and / or alcohol abuse 2 years prior to the screening period
  • One or more of the laboratory findings fall out of the limitations for this study(platelet,hemoglobin,aspartate aminotransferase,etc.)
  • Pregnant women or those in lactation period
  • Allergic to drugs used in the study
  • Patients with respiratory management difficulties (Modified Mallampati grade IV)
  • Patients have participated in other clinical trial within the 3 months prior to randomization
  • Any patient judged by the Principal Investigator (PI) or Sub-Investigator to be inappropriate for the subject for any other reason

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Peking Union Medical College Hospital

Beijing, Beijing Municipality, 010, China

Location

MeSH Terms

Interventions

Propofol

Intervention Hierarchy (Ancestors)

PhenolsBenzene DerivativesHydrocarbons, AromaticHydrocarbons, CyclicHydrocarbonsOrganic Chemicals

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 15, 2019

First Posted

April 19, 2019

Study Start

May 13, 2019

Primary Completion

December 30, 2019

Study Completion

December 30, 2019

Last Updated

May 15, 2020

Record last verified: 2020-05

Locations